title: Small intestinal bacterial overgrowth and Helicobacter pylori: can they be cause of thrombocytopenia in patients with chronic liver disease?
authors.forename: Edoardo
authors.initials: E
authors.lastname: Savarino
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Assandri
authors.forename: Edoardo G
authors.initials: EG
authors.lastname: Giannini
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Savarino
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D000890:Anti-Infective Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects / Q000254:growth & development; D007421:Intestine, Small / Q000187:drug effects / Q000382:microbiology; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D012294:Rifamycins / Q000627:therapeutic use; D000078262:Rifaximin; D018570:Risk Assessment; D013921:Thrombocytopenia / Q000209:etiology / Q000503:physiopathology; D016896:Treatment Outcome; D016032:Randomized Controlled Trials as Topic
chemical_list: D000890:Anti-Infective Agents; D012294:Rifamycins; D000078262:Rifaximin